Rome-based medtech company MEDICUD, which develops portable wound therapy systems, has secured €1.3 million in a seed funding round led by CHMBR Partners. The funding will support clinical trials and regulatory development of DRYUM for orthopedic surgery.
- Founded in 2020 by Antonio d’Angelo and Andrea Cazzulani, MEDICUD develops DRYUM, an ultraportable incisional negative pressure wound therapy system.
- DRYUM delivers constant negative pressure manually, promoting healing and reducing complications like infections and dehiscence.
- The device is still in clinical trials, manual, lightweight, and made with bio-sourced polymers, without embedded electronics.
“I am proud of what we have accomplished at Medicud. The team worked tirelessly to develop the DRYUM device and make it work in the shortest time possible. Clinicians need a new standard of care for wound healing, both cost effective and efficient in reducing surgical complications, and more sustainable,” claims Antonio Nunzio d’Angelo, CEO and co-founder of Medicud.
Details of the deal
- The investment was led by US investor CHMBR Partners, with support from Paris-based accelerator 50 Partners Capital Health, which backs healthcare startups, and Business Angels des Grandes Écoles (BADGE), as well as notable business angels.
“We invest in promising companies in sports and health in three areas: biotech, medtech, and consumer-facing technologies. Medicud falls squarely within these boundaries. It opens up a market that was previously not attractive due to excessive pricing and minimal benefits compared to simple bandages,” Managing Member of CHMBR Partners, LLC, Charles Hirschler, commented.
- The startup will use the fresh funding to support the clinical and regulatory development of DRYUM, focusing on launching a pivotal trial for orthopedic surgery. The financing will assist with the regulatory process, including completing the CE mark and FDA approval for commercialization.
- Additionally, the funds will help expand the team, particularly by hiring a commercial director, and accelerate clinical development to bring DRYUM closer to market.
